Total submissions: 19
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000254727 | SCV000321383 | pathogenic | not provided | 2025-01-24 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Also known as p.V128M; This variant is associated with the following publications: (PMID: 32860008, 31130284, 37644014, 34374989, 26633546, 25558065, 30296593, 30529455, 31263000, 32552793, 32214227, 33101984, 28454995, 30202406, 35118659, 26842963, 23620220, 38168508) |
Broad Center for Mendelian Genomics, |
RCV000162122 | SCV000786718 | pathogenic | Intellectual disability-strabismus syndrome | criteria provided, single submitter | research | The homozgous p.Val144Met variant was identified by our study in one individual with mental retardation. Of note, a first cousin who was noted to also have mental retardation was a carrier for this variant. The p.Val144Met variant is believed to be pathogenic based on numberous reports by other laboratories in the literature and databases. | |
Pathology and Clinical Laboratory Medicine, |
RCV000162122 | SCV000996290 | pathogenic | Intellectual disability-strabismus syndrome | criteria provided, single submitter | clinical testing | ||
Centogene AG - |
RCV000162122 | SCV001426529 | pathogenic | Intellectual disability-strabismus syndrome | criteria provided, single submitter | clinical testing | ||
Baylor Genetics | RCV000162122 | SCV001521996 | pathogenic | Intellectual disability-strabismus syndrome | 2020-06-03 | criteria provided, single submitter | clinical testing | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. |
Department of Biochemistry, |
RCV000162122 | SCV001547514 | pathogenic | Intellectual disability-strabismus syndrome | 2021-03-25 | criteria provided, single submitter | research | We detected the variant NM_138422.3(ADAT3): c.430G>A (p.Val144Met, rs730882213) in two female siblings with Mental retardation, autosomal recessive 36 using whole-exome sequencing. We validated the variant's status in the patients using Sanger sequencing and detected it in a heterozygous status in their parents. Multiple reports previously classified the variant NM_138422.3(ADAT3): c.430G>A (p.Val144Met, rs730882213) as pathogenic (Alazami et al., 2013; El-Hattab et al., 2016). |
Revvity Omics, |
RCV000162122 | SCV002022276 | pathogenic | Intellectual disability-strabismus syndrome | 2022-07-06 | criteria provided, single submitter | clinical testing | |
Hadassah Hebrew University Medical Center | RCV000162122 | SCV004099517 | likely pathogenic | Intellectual disability-strabismus syndrome | criteria provided, single submitter | clinical testing | ||
Institute of Human Genetics, |
RCV000162122 | SCV004171164 | pathogenic | Intellectual disability-strabismus syndrome | criteria provided, single submitter | not provided | ||
Genomic Medicine Center of Excellence, |
RCV000162122 | SCV004804796 | likely pathogenic | Intellectual disability-strabismus syndrome | 2024-03-17 | criteria provided, single submitter | research | |
Breakthrough Genomics, |
RCV000162122 | SCV005088727 | pathogenic | Intellectual disability-strabismus syndrome | 2021-06-23 | criteria provided, single submitter | clinical testing | This variant is predicted to be damaging by in-silico missense prediction tools (SIFT and Polyphen2). The variant (also known as V128M in literature) was previously reported in patients with intellectual disability and considered as founder mutation in the Saudi Arabian population [PMID: 26842963, 23620220, 32214227]. Functional studies using cell lines derived from intellectual disability-affected individuals showed a severe reduction in tRNA deaminase activity [PMID: 31263000]. |
Al Jalila Children’s Genomics Center, |
RCV004798787 | SCV005420574 | pathogenic | Neurodevelopmental disorder with brain abnormalities | 2024-10-04 | criteria provided, single submitter | research | PM3,PS3,PM2,PP3 |
Institute of Medical Genetics and Applied Genomics, |
RCV000162122 | SCV005848182 | pathogenic | Intellectual disability-strabismus syndrome | 2025-02-18 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000162122 | SCV000082799 | pathogenic | Intellectual disability-strabismus syndrome | 2013-07-01 | no assertion criteria provided | literature only | |
Genomic Medicine Center of Excellence, |
RCV000162122 | SCV000196407 | likely pathogenic | Intellectual disability-strabismus syndrome | 2014-12-01 | no assertion criteria provided | research | |
Biochemical Molecular Genetic Laboratory, |
RCV000162122 | SCV001132975 | pathogenic | Intellectual disability-strabismus syndrome | 2019-08-25 | no assertion criteria provided | clinical testing | |
Section for Clinical Neurogenetics, |
RCV000162122 | SCV001156076 | pathogenic | Intellectual disability-strabismus syndrome | 2019-08-01 | no assertion criteria provided | research | |
Genome Diagnostics Laboratory, |
RCV000254727 | SCV001977665 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000254727 | SCV001979423 | likely pathogenic | not provided | no assertion criteria provided | clinical testing |